This 161519 TriKE was developed for treatment of CD19-positive cancers and was designed to redirect NK cells via their CD16 to kill CD19+ target cells; meanwhile, IL-15 aided the development, proliferation, and survival of NK cells. The gene discussed is FCGR3A; the disease is cancer.